西格列汀联合门冬胰岛素30治疗2型糖尿病的临床观察

Clinical observation on sitagliptin combined BIAsp30 in the treatment of type 2 diabetes

目的:观察西格列汀联合门冬胰岛素30治疗2型糖尿病的有效性及安全性。方法:将口服降糖药治疗效果差且病程较长的2型糖尿病患者80例随机分为实验组和对照组各40例。实验组给予西格列汀联合门冬胰岛素30治疗,对照组给予门冬胰岛素30胰岛素治疗。观察2组患者治疗第0,8,16周时FBG(空腹血糖)、2hBG(餐后2h血糖)、HbA1c(糖化血红蛋白)、胰岛素用量和BMI值。第16周时检测2组患者C肽水平,并进行比较。结果:治疗后8、16周后,2组患者的FBG、2hBG和HbA1c均显著下降,与治疗前相比差异具有显著性(P<0.05)。同时实验组FBG、2hBG和HbA1c较对照组显著下降(P<0.05)。治疗16周后,实验组的BMI和胰岛素用量均显著低于对照组,而C肽水平显著高于对照组(P<0.05)。结论:口服降糖药治疗效果差且病程较长的2型糖尿病应用西格列汀联合门冬胰岛素30可获得良好的血糖控制,同时可改善胰岛功能,减少体质量增加,减少低血糖发生,安全有效。

OBJECTIVE To explore the effect and safety of combination of sitagliptin and BIAsp30 in the treatment of pa tients with type2 diabetes. METHODS 80 cases of type 2 diabetes patients who had inefficacious treatment with long history of taking oral hypoglyeemic drugs were selected. Totally 80 patients were randomly divided into experimental group and control group. Experimental group received sitagliptin combined BIAsp30 treatment for 16 weeks,and control group received BIAsp30 therapy. Fasting blood glucose （FBG）, 2h postprandial blood glucose （2hPG）, glycosylated hemoglobin （HbA, c）, insulin dose and BMI of two groups were measured on week 0, 8, and 16 respectively. C peptide levels were also detected on week 16. RESULTS FBG, 2hPG, HbAlc of two groups decreased significantly on week 8 and 16（P^0./15）. Compared with control group, FBG, 2hPG, HbAlc of experimental group decreased significantly （P%0. （/5）. After 16 weeks, the insulin dose and BMI of experimental group were much lower than those of control group （P%0.05）, but C peptide levels of experimental group were much higher than those of control group （P＊^（I. 05）. CONCLUSION Combination of sitagliptin and BIAsp30 can significantly decrease blood glucose, improve insulin function, reduce weight gain and hypoglycemia episodes, which indicate it is a safe and effective therapy strategy for patients with type 2 diabetes.